Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
39
KMTS Quote, Financials, Valuation and Earnings
Last price:
$27.97
Seasonality move
:
--
Day range:
$26.72 - $28.84
52-week range:
$13.25 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.37x
P/B ratio:
8.13x
Volume:
344.1K
Avg. volume:
386.5K
1-year change:
--
Market cap:
$1.3B
Revenue:
$59.8M
EPS (TTM):
-$2.68
Analysts' Opinion
-
Consensus RatingKestra Medical Technologies Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.14, Kestra Medical Technologies Ltd. has an estimated upside of 4.05% from its current price of $28.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $28.01.
Fair Value
-
According to the consensus of 6 analysts, Kestra Medical Technologies Ltd. has 4.05% upside to fair value with a price target of $29.14 per share.
KMTS vs. S&P 500
-
Over the past 5 trading days, Kestra Medical Technologies Ltd. has overperformed the S&P 500 by 3.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kestra Medical Technologies Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kestra Medical Technologies Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kestra Medical Technologies Ltd. reported revenues of $22.6M.
Earnings Growth
-
Kestra Medical Technologies Ltd. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Kestra Medical Technologies Ltd. reported earnings per share of -$0.64.
Enterprise value:
1.2B
EV / Invested capital:
5.76x
Price / LTM sales:
19.37x
EV / EBIT:
--
EV / Revenue:
16.21x
PEG ratio (5yr expected):
-0.25x
EV / Free cash flow:
-10.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$34.5M
Return On Assets:
-63.04%
Net Income Margin (TTM):
-177.06%
Return On Equity:
-105.99%
Return On Invested Capital:
-77.65%
Operating Margin:
-140.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Income Statement | ||||||
| Revenue | -- | $45.8M | $74.3M | $14.7M | $22.6M | |
| Gross Profit | -$1.9M | $12.3M | $34.5M | $5.8M | $11.4M | |
| Operating Income | -- | -$77.9M | -$129.4M | -$19.1M | -$31.8M | |
| EBITDA | -- | -$35.8M | -$121.3M | -$17.3M | -$29.4M | |
| Diluted EPS | -$1.07 | -$1.89 | -$2.68 | -$0.48 | -$0.64 | |
| Period Ending | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $87.9M | $195.4M | |
| Total Assets | -- | -- | -- | $126.1M | $246.7M | |
| Current Liabilities | -- | -- | -- | $31.3M | $35.8M | |
| Total Liabilities | -- | -- | -- | $82.1M | $82.6M | |
| Total Equity | -- | -- | -- | $44M | $164.1M | |
| Total Debt | -- | -- | -- | $46.1M | $44.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$66.3M | -$86.7M | -$18M | -$18.3M | |
| Cash From Investing | -- | -$20.6M | -$10.4M | -$21.6M | -$7.4M | |
| Cash From Financing | -- | $139.8M | $195.6M | $16.5M | -$27K | |
| Free Cash Flow | -- | -$86.9M | -$114.6M | -$22.5M | -$25.8M | |
KMTS
Sector
Market Cap
$1.3B
--
Price % of 52-Week High
93.37%
--
Dividend Yield
0%
--
Shareholder Yield
-15.68%
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$26.73
200-day SMA
Buy
Level
$21.77
Bollinger Bands (100)
Buy
Level
18.52 - 27.04
Chaikin Money Flow
Buy
Level
1.9M
20-day SMA
Buy
Level
$25.90
Relative Strength Index (RSI14)
Buy
Level
62.24
ADX Line
Buy
Level
12.32
Williams %R
Sell
Level
-15.4278
50-day SMA
Buy
Level
$25.88
MACD (12, 26)
Buy
Level
0.46
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
11.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.0491)
Sell
CA Score
(Annual)
Level (-3.0997)
Sell
Beneish M-Score
(Annual)
Level (-1.7818)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (2.5512)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kestra Medical Technologies Ltd. is a commercial-stage, wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Phillip D. Foshee in 2014 and is headquartered in Kirkland, WA.
Stock Forecast FAQ
In the current month, KMTS has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KMTS average analyst price target in the past 3 months is $29.14.
-
Where Will Kestra Medical Technologies Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kestra Medical Technologies Ltd. share price will rise to $29.14 per share over the next 12 months.
-
What Do Analysts Say About Kestra Medical Technologies Ltd.?
Analysts are divided on their view about Kestra Medical Technologies Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kestra Medical Technologies Ltd. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Kestra Medical Technologies Ltd.'s Price Target?
The price target for Kestra Medical Technologies Ltd. over the next 1-year time period is forecast to be $29.14 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KMTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kestra Medical Technologies Ltd. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KMTS?
You can purchase shares of Kestra Medical Technologies Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kestra Medical Technologies Ltd. shares.
-
What Is The Kestra Medical Technologies Ltd. Share Price Today?
Kestra Medical Technologies Ltd. was last trading at $27.97 per share. This represents the most recent stock quote for Kestra Medical Technologies Ltd.. Yesterday, Kestra Medical Technologies Ltd. closed at $28.01 per share.
-
How To Buy Kestra Medical Technologies Ltd. Stock Online?
In order to purchase Kestra Medical Technologies Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KMTS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KMTS
Sector
P/E ratio
--
--
PEG ratio
-0.25x
--
P/B ratio
8.13x
--
Price / LTM sales
19.37x
--
Growth Metrics
KMTS
Sector
Revenue growth
53.4%
--
Earnings growth
-33.41%
--
Revenue (5-year growth)
--
--
Earnings forecast
-$0.57
--
Profitability
KMTS
Sector
Profitability FY 2025
$24.2M
--
Return on invested capital
-77.65%
--
Return on assets
-63.04%
--
Return on equity
-105.99%
--
Earnings Date
Last Earnings Date
Dec
11
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Mar
12
Balance Sheet
KMTS
Sector
Total cash
$175.4M
--
Short term investments
--
--
Total assets
$295.7M
--
Long term debt
$44.7M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 24.71% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 20.67% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is up 19.65% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
